Please login to the form below

Not currently logged in
Email:
Password:

Swedish regulator rules Boehringer press release is advertising

German pharma company fails to appeal decision

Boehringer Ingelheim headquarters

The Swedish Medical Products Agency (MPA) has upheld its decision to prevent Boehringer Ingelheim from using a press release about its oral anticoagulant Pradaxa (dabigatran).

The medicines regulator ruled that the press release constituted advertising a prescription-based product to the general public – which is prohibited under Swedish and European law.

The release publicised the company's plans to lower the price for Pradaxa in Sweden and was published on the journalist website mynewsdesk.com in May 2011.

Boehringer Ingelheim Pradaxa dabigatran packMPA's assessment of the press release was that it had addressed the public with positive information about the product and therefore breached Swedish regulations.

Boehringer appealed the MPA's initial September 2011 ruling, but the company's bid has now failed.

In a written comment on the case, legal firm Bird & Bird said: "The Agency […] stated that the text in the press release has clear advertising character which only describes the advantages of the product with no mention of the disadvantages."

However, the firm added: "The 'public' in this case comprised journalists, as the press release was explicitly targeted at journalists."

Throughout its appeal, Boehringer contended the press release should not be construed as advertising, arguing that it "followed old established praxis regarding issuing press releases in Sweden," and that such communications were protected as freedom of speech.

Following the verdict, the president of the Swedish pharmaceutical trade association LIF, Anders Blanck, expressed his disappointment at the decision.

He said the court has "chosen to completely ignore the clear and long-established practice" of providing journalists with press releases.

Blanck added: "We will now analyse the judgement in detail, and may later decide [if] LIF and the company concerned will proceed in the matter."

25th February 2013

From: Marketing, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...